The gold standard is the Abnormal Involuntary Movement Scale, or the AIMS, although generally we kind of want to avoid premature TD labels, and we want to ensure that there's a causal link, in this ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is ...
Accurate and early diagnosis of tardive dyskinesia (TD), a serious movement disorder typically caused by exposure to antipsychotic medications, is imperative for long-term management. "Keeping an eye ...
Currently there are two FDA approved treatment options for tardive dyskinesia. There are two medications that are VMAT2 inhibitors. These are valbenazine (Ingrezza) and deutetrabenazine (Austedo) made ...
Neurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness Week
Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9147351-neurocrine-biosciences-tardive-dyskinesia-awareness ...
The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from ...
Hosted on MSN
Could Aspartame Play a Role in Tardive Dyskinesia?
Aspartame is considered safe within daily limits, yet researchers are studying whether it may affect tardive dyskinesia. Here’s what early findings suggest. Aspartame is one of the most commonly used ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results